Expression of WNT1 in ameloblastoma and its significance

GUAN-NAN WANG¹², MING ZHONG¹, YV CHEN¹, JIA JI¹, XIU-QIU GAO³ and TIAN-FU WANG⁴

¹Department of Pathology, Stomatological Hospital of China Medical University, Shenyang, Liaoning 110002; ²Basic Medicine College; ³Department of Oral Medicine, Second Affiliated Hospital, Jinzhou Medical University; ⁴Liaoning Railway Vocational and Technical College, Jinzhou, Liaoning 121000, P.R. China

Received September 29, 2016; Accepted April 16, 2018

DOI: 10.3892/ol.2018.8820

Abstract. The present study aimed to measure the expression of WNT1 in ameloblastoma (AB). Immunohistochemistry was used to observe changes in WNT1 expression in 80 AB samples, 10 keratocystic odontogenic tumor (KCOT) samples and 10 normal oral mucosa (NOM) samples. Western blotting and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) were used to measure WNT1 protein and mRNA expression, respectively, in 30 AB samples, 5 KCOT samples, 5 NOM samples and 3 tooth germ samples. Ectopic cytoplasmic expression of WNT1 was detected in AB; 88.8% (71/80) of the samples were WNT1-positive. The western blotting results demonstrated that compared with NOM (0.57±0.05), WNT1 expression was significantly higher in AB tissue (1.74±0.36, P<0.05), whereas it was not significantly different between AB and KCOT samples (0.80±0.06, P>0.05). RT-qPCR revealed that the level of WNT1 gene expression in AB was increased 2.43-fold compared with normal mucosa, and 1.77-fold compared with tooth germ tissue. In conclusion, WNT1 protein and mRNA expression were increased in AB, and there was ectopic cytoplasmic expression. This indicates that WNT1 may serve an important role in AB occurrence and development.

Introduction

The development of ameloblastoma (AB) may be similar to tooth germ development, as it is likely derived from the epithelial lining of the dental follicle, the epithelial residue of the tooth plate and the basal cells of the oral mucosa (1).

From C. elegans to humans, WNT genes are conserved across many species. Previous studies have demonstrated that WNT1 is a key signal molecule for controlling cell growth and proliferation. It transfers regulatory information between cells, and serves an important role in stem cell differentiation and neural development. Kumamoto and Ooya (2) reported that WNT pathway abnormalities induce tumor occurrence, as WNT1 activation phosphorylates β-catenin in the nucleus to activate the classic WNT pathways, inducing cell proliferation and inhibiting apoptosis to generate anomalous growth.

As the effect of the WNT signaling pathway in the process of tooth development is well characterized, and as multiple associated factors are expressed during different developmental periods of the tooth germ (3), we hypothesized that this pathway may be associated with the development of AB. Therefore, immunohistochemistry, western blotting and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) were used to examine WNT1 expression in AB, with the aim of providing a basis for diagnosing and treating AB.

Materials and methods

Tissue samples. Immunohistochemical specimens were obtained from paraffin blocks archived at the Department of Oral Pathology, Stomatological Hospital of China Medical University (Shenyang, China), between June 2009 and April 2013. The study protocol was approved by the Medical Ethics Committee of Stomatological Hospital of China Medical University. The study was performed in accordance with the Declaration of Helsinki. All specimens were analyzed subsequent to obtaining verbal informed patient consent. This was not a retrospective study. There were 80 cases of AB (Table I) with no chemotherapy or radiotherapy administered prior to tissue extraction, 10 of keratocystic odontogenic tumor (KCOT) and 10 samples of normal oral mucosa (NOM). There were 40 male and 40 female patients with AB; the age range was 18-79 years and the median age was 49 years. All specimens were classified according to the 2005 World Health Organization (WHO) criteria (4). The areas the tumor tissue was extracted from included the mandible (65 cases), maxilla (12 cases) and gingiva (3 cases). The histological types were as follows: 76.3% (61/80) solid/polycystic, 1.6% (13/80) unicystic, 3.8% (3/80) desmoplastic and 3.8% (3/80) peripheral. Of the solid type, 42 cases were typed as follicular, 5 as plexiform, 7 as follicular/plexiform, 3 as acanthomatous, 2 as basal cell and 2 as keratinous.

The fresh tissue samples obtained between January 2004 and December 2009 for western blotting and RT-qPCR

Correspondence to: Dr Ming Zhong, Department of Pathology, Stomatological Hospital of China Medical University, 117 Nanjing Street North, Heping, Shenyang, Liaoning 110002, P.R. China

E-mail: zhongming_oral@aliyun.com

Key words: ameloblastoma, WNT1, immunohistochemistry, western blot
were surgical resection specimens from the Department of Oral and Maxillofacial Surgery, Stomatological Hospital of China Medical University. The samples included 30 cases of AB (Table II), 5 cases of KCOT, and 5 NOM samples. In addition, 3 cases of tooth germ tissue were abortuses from the Department of Obstetrics of the People’s Liberation Army no. 202 Hospital (Shenyang, China). The samples were cryo-preserved at -86°C and were classified according to the 2005 WHO criteria. There were 16 male and 14 female patients with AB; the age range was 16-72 years, and the median age of which was 44 years. The areas involved included the mandible (24 cases), maxilla (3 cases), gingiva (1 case), left parapharyngeal space palate (1 case) and left cheek (1 case). The histological type was as follows: 83.3% (25/30) were solid/polycystic, 3.3% (1/30) unicuscent, 3.3% (1/30) desmoplastic and 10% (3/30) peripheral. Of the solid type, 14 were follicular, 5 plexiform, 3 acanthomatous, 2 basal cell and 1 follicular/plexiform.

**Immunohistochemistry.** Sections (5 µm) were obtained from the paraffin-embedded tissues of the first group. Following the inactivation of endogenous peroxidase by quenching with 

\[ \text{H}_2\text{O}_2, \]

sections were treated overnight with a goat anti-WNT1 polyclonal primary antibody (dilution, 1:400; Abcam, Cambridge, MA, USA; cat no. ab15251) at 4°C. The streptavidin-peroxidase (SP) method was used; an SP kit (Zymed; Thermo Fisher Scientific, Inc., Waltham, MA, USA) contained biotinylated streptavidin and peroxidase. The secondary antibody was alkaline phosphatase-labeled anti-goat IgG (dilution, 1:1,000; cat no. A01030; Abbkine Scientific Co., Ltd., Wuhan, China). The 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium Alkaline Phosphatase Color Development kit was used as the primary antibody; the secondary antibody was alkaline phosphatase-labeled anti-goat IgG (dilution, 1:1,000; cat no. A0208; Seikagaku Corporation, Tokyo, Japan). β-tubulin was used as the internal control antibody (dilution, 1:1,000; cat no. A01030; Abbkine Scientific Co., Ltd., Wuhan, China). The 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium Alkaline Phosphatase Color Development kit was used for visualization (cat no. C3206; Beyotime Institute of Biotechnology, Jiangsu, China). AlphaView 2.0 gel imaging analysis software (ProteinSimple; Bio-Techne, Minneapolis, MN, USA) was used for quantitative analysis.

**Western blot.** Pre-made protein cracking fluid (20 mmol/l Tris-HCL pH 7.4, 150 mmol/l NaCl, 1% Triton X-100, 0.1% SDS, 1% deoxycholic acid sodium, 1 mmol/l EDTA, 1 mmol/l PMSF, 1 µg/ml aprotinin, 1 mmol/l NaN_3VO_3) was used to extract proteins and extracted proteins were separated using SDS-PAGE (12% separation polyacrylamide gel and 4% polyacrylamide concentration gel). The amount of protein per lane was 38.8 µg. The coomassie brilliant blue method (6) was used for protein quantification. The proteins were transferred to a nitrocellulose membrane (Biomol; Enzo Life Sciences, Inc., Farmingdale, NY, USA) and blocked with Tween-20 in Tris-buffered saline containing 5% non-fat dry milk overnight at 4°C. The goat anti-human WNT1 polyclonal antibody (dilution, 1:400; cat no. ab15251; Abcam) was used as the primary antibody; the secondary antibody was alkaline phosphatase-labeled anti-goat IgG (dilution, 1:1,000; cat no. A0208; Seikagaku Corporation, Tokyo, Japan). β-tubulin was used as the internal control antibody (dilution, 1:1,000; cat no. A01030; Abbkine Scientific Co., Ltd., Wuhan, China). The 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium Alkaline Phosphatase Color Development kit was used for visualization (cat no. C3206; Beyotime Institute of Biotechnology, Jiangsu, China). AlphaView 2.0 gel imaging analysis software (ProteinSimple; Bio-Techne, Minneapolis, MN, USA) was used for quantitative analysis.

**RT-qPCR.** TRIzol (Invitrogen; Thermo Fisher Scientific, Inc.) was used to extract total RNA, and cDNA was synthesized with reverse transcription using the PrimeScript One Step RT-PCR kit Ver.2 (cat no. RR055A; Takara Biotecology Co., Ltd., Dalian, China). PCR amplification of the cDNA was performed in 20 µl mixtures according to the protocol...
of the SYBR Premix Ex Taq™ II kit (cat no. RR820A; Takara Biotechnology Co., Ltd.). The thermocycling conditions were as follows: Initial denaturation stage at 95˚C for 30 sec, followed by 40 cycles of denaturation at 95˚C for 5 sec, and then primer annealing and template amplification at 60˚C for 34 sec. Primer3 software was used to design the PCR primers, which were synthesized by Beijing Genomics Institute (Beijing, China) (Table III).

\[
\begin{array}{ccc}
\text{Gene} & \text{Primers} & \text{Sequence} & \text{Product size, bp} \\
\hline
\text{WNT1} & \text{Upstream} & 5'\text{CAGCGCAACAACCCAAGTC} - 3' & 107 \\
& \text{Downstream} & 5'\text{GCAGCAGCGTAGCAGAAAC} - 3' \\
\text{ACTB} & \text{Upstream} & 5'\text{AGGTTGCCTTACACCCCTTTTC} - 3' & 492 \\
& \text{Downstream} & 5'\text{TGTACCACTTTACCGTTCC} - 3' \\
\end{array}
\]

ACTB, β-actin.

Table III. WNT1 and ACTB primers.

Table IV. Difference in WNT1 expression between AB and NOM as determined by immunohistochemistry.

| Tissue type | n | Positive | Negative | \(\chi^2\) | P-value |
|-------------|---|----------|----------|--------------|---------|
| AB          | 80| 71       | 9        | 36.88        | <0.001  |
| NOM         | 10| 0        | 10       |              |         |

AB, ameloblastoma; NOM, normal oral mucosa.

Table V. Difference in WNT1 expression between AB and KCOT tissues as determined by immunohistochemistry.

| Tissue type | n | Positive | Negative | \(\chi^2\) | P-value |
|-------------|---|----------|----------|--------------|---------|
| AB          | 80| 71       | 9        | 1.325        | 0.25    |
| KCOT        | 10| 7        | 3        |              |         |

AB, ameloblastoma; KCOT, keratocystic odontogenic tumor.

Table VI. Difference in WNT1 expression between different types of AB as determined by immunohistochemistry.

| AB type | n | Positive | Negative | \(\chi^2\) | P-value |
|---------|---|----------|----------|--------------|---------|
| Solid/polycystic | 61| 55 | 6 | 2.073 | 0.56 |
| Unicystic | 13| 11 | 2 | | |
| Desmoplastic | 3| 2 | 1 | | |
| Peripheral | 3| 3 | 0 | | |

AB, ameloblastoma.

Statistical analysis. Data are presented as the mean ± standard error of the mean. All experiments were conducted with a minimum of three repeats. Statistical analysis was performed using SPSS 17.0 software. \(\chi^2\) tests and one-way analysis of variance followed by Fisher's least significant difference tests were used for the comparisons. \(P<0.05\) was considered to represent a statistically significant difference.

Results

WNT1 protein expression is increased in AB, as determined with immunohistochemistry. WNT1 expression in NOM was negative for all samples (Fig. 1A) while there was positive WNT1 expression in 70% of KCOT samples (7/10); WNT1 was expressed in the cytoplasm of the lining epithelial cells, and staining was generally weak-to-moderately positive (Fig. 1B). There was positive WNT1 expression in 89% of AB samples (71/80); staining was predominantly moderately or strongly positive in the outer periphery of the columnar or cuboidal cells of the dental epithelium, the cytoplasm of the central stellate reticular layer, and the inflammatory interstitial lymphocytes (Fig. 1C-F).

As shown by Tables IV-VI, WNT1 expression in AB was significantly higher than in NOM (\(P<0.001\)), but not significantly different from in KCOT (\(P>0.05\)). There was no significant difference between AB types (\(P>0.05\)).

WNT1 protein expression is increased in AB, as determined with western blotting. The WNT1 protein expression level in each sample was determined with western blotting (Fig. 2A); expression levels in AB, KCOT and NOM were 1.74±0.36, 1.31±0.06, and 0.57±0.05 (Fig. 2B). WNT1 expression in AB was significantly higher than in NOM (\(P<0.05\)), but not significantly different from in KCOT (\(P>0.05\)).

WNT1 mRNA expression is increased in AB, as determined with RT-qPCR. RT-qPCR was used to assess the WNT1 mRNA expression level in 30 AB, 3 tooth germ and 5 NOM tissue
The WNT signaling pathway is named for its initiating protein, WNT1; WNT1 is the first member of the 19-member WNT gene family and encodes a 370-amino acid protein (8). Howe et al (9) reported that WNT1 induces overexpression of downstream target genes by activating the WNT/\beta
catenin signaling pathway, resulting in excessive cell growth. The diverse biological effects of WNT signaling include the regulation of cell proliferation, morphogenesis, and cell survival and death processes; abnormal activation of WNT signaling is associated with a variety of developmental disorders, degenerative diseases, types of cancer e.g. colon cancer (10), retinopathy (11),
limbless malformations (12), and bone and cartilage diseases, including arthritis (13). WNT1 is a tumor-associated protein which is upregulated in breast cancer, hepatocellular carcinoma, oral carcinoma, colorectal cancer and other types of epithelial malignancy; it may be involved in the occurrence of these tumors (14-17). Joeng et al demonstrated that WNT1 effectively reduced β-catenin expression in the cytoplasm, and induced apoptosis by recovering the function of WNT inhibitory factor-1 (WIF-1) in colon cancer cells, increasing WNT siRNA or using anti-WNT monoclonal antibodies (18).

In the present study, WNT1 expression was positive in 71 cases of AB; of these, expression was strongly positive in 60 cases (84.5%) and weakly positive in 11 cases (15.5%), suggesting heterogeneity in WNT1 expression intensity in AB. In addition, WNT1 was expressed only in the cytoplasm of tumor cells, and not in the nucleus. WNT1 was expressed in the peripheral cells of tumor cell nests and the stellate reticular cell layer. We hypothesize that positive WNT1 expression in tumor-adjacent tissues may be associated with the invasiveness of AB. Positive WNT1 expression was also detected in cells surrounding the epithelial islands of follicular and acanthoma AB, reflecting the importance of WNT1 signaling in cell proliferation (19). However, it is difficult to compare the difference in WNT1 content using only immunohistochemical staining.

Western blotting demonstrated that WNT1 levels in the tumor tissue were significantly higher than in NOM tissue, suggesting that WNT1 expression was enhanced in AB. RT-qPCR was used to determine that WNT1 mRNA levels in 30 cases of AB were 2.43 times higher than that in NOM tissue, suggesting that WNT1 expression is enhanced at mRNA level. As mRNA levels directly reflect gene expression, they support the hypothesis that WNT1 gene activation is associated with AB. The mechanisms for the activation of the WNT1 gene in AB has yet to be determined.

The WNT gene was designated as such as it contains a virus integration site; such integration sites are also present upstream of the WNT1 gene promoter (20). Papillary ductal carcinoma of the breast is potentially induced by human papilloma virus infection, and high WNT1 mRNA expression has been detected in tumors of this type (14). Integrating a viral gene into the viral integration site upstream of the WNT1 gene promoter induces mammary tumor formation (20), suggesting that the activation of the WNT1 gene in cancer may be associated with the transfection of viral genes. As AB development due to viral infection has never been reported, further studies are warranted to determine whether there are mutations at the WNT1 gene regulatory site.

Immunohistochemical results of this study showed that the expression level of WNT1 was significantly higher in the AB than in normal oral mucosa tissues, combined with western blotting and RT-qPCR results suggest that WNT1 and the occurrence of ABs and its aggressive has a high correlation. Through the study of biological behavior of AB and the relationship between WNT1 expression, WNT1 could also be the diagnosis and evaluation of prognosis of effective index of AB. For this reason, the WNT1 as a target genes to treat AB is helpful.

**Figure 3.** Reverse transcription-qPCR determination of WNT1 expression levels in AB and NOM. (a) Amplification curve for qPCR. (b) Dissolution curve for qPCR. (c) WNT1 mRNA expression level was higher in ABs than in NOM or tooth germ tissue. qPCR, quantitative polymerase chain reaction; AB, ameloblastoma; NOM, normal oral mucosa. *P<0.05 vs. NOM.
Acknowledgements

Not applicable.

Funding

The present study was supported by the National Natural Science Foundation Project of China (grants nos. 30672323 and 81072197).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

GW performed the immunohistochemical, western blot analysis and RT-qPCR experiments and was a major contributor in writing the manuscript. MZ made substantial contributions to conception and design. YC and JJ collected and organized the data of 80 patients with ameloblastoma. XG and TW performed the statistical analysis of data. All authors reviewed the final manuscript and approved it for publication.

Ethics approval and consent to participate

The study protocol was approved by the Medical Ethics Committee of Stomatological Hospital of China Medical University. The study was performed in accordance with the Declaration of Helsinki. Informed verbal patient consent was obtained for the use of all specimens.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Kharashevili G, Simkova D, Makharobidze E, Trtikova K, Kolar Z and Bouchal J: Wnt signaling in prostate development and carcinogenesis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 155: 11-18, 2011.
2. Kumamoto H and Ooya K: Immunohistochemical detection of beta-catenin and adenomatous polyposis coli in ameloblastomas. Oral Pathol Med 34: 401-406, 2005.
3. Peng L, Ye L, Dong G, Ren LB, Wang CL, Xu P and Zhou XD: WNT5A inhibits human dental papilla cell proliferation and migration. Biochem Biophys Res Commun 390: 1072-1078, 2009.
4. Barnes L, Eveson JW, Reichart P and Sidransky D: Pathology and Genetics of Head and Neck Tumours. In: World Health Organization Classification of Tumours. IARC Press, Lyon, 2006.
5. Li TJ, Wu YT, Yu SF and Yu GF: Unicystic ameloblastoma: A clinicopathologic study of 33 Chinese patients. Am J Surg Pathol 24: 1385-1392, 2000.
6. Gritzalis K, Georgiou CD and Schneider YJ: An accurate and sensitive Coomassie brilliant blue G-250-based assay for protein determination. Anal Biochem 480: 28-30, 2015.
7. Livak KJ and Schmittgen TD: Analysis of relative gene expression using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
8. Reya T and Clevers H: Wnt signalling in stem cells and cancer. Nature 434: 843-850, 2005.
9. Howe LR, Subbaramaiah K, Chung WJ, Dannenberg AJ and Brown AM: Transcriptional activation of cyclooxygenase-2 in Wnt-1 transformed mouse mammary epithelial cells. Cancer Res 59: 1572-1577, 1999.
10. Yoshida N, Kimugasa T, Ohshima K, Yuge K, Okuchi T, Fujino S, Shiraaiwa S, Katagiri M and Akagi Y: Analysis of Wnt and beta-catenin expression in advanced colorectal cancer. Anticancer Res 35: 4403-4410, 2015.
11. Wittkorn E, Sarkar A, Garcia K, Kango-Singh M and Singh A: The Hippo pathway effector Yki downregulates Wg signaling to promote retinal differentiation in the Drosophila eye. Developmental 142: 2002-2013, 2015.
12. Liu B, Chen S, Cheng D, Jing W and Helms JA: Primary cilia integrate hedgehog and Wnt signaling during tooth development. J Dent Res 93: 475-482, 2014.
13. Maasuksi K, Nikopoulos T, Koiks S, Noutsas M, Kals M, Prans E, Zhytnik L, Metsalu P and Märtson A: Whole-exome sequencing identifies de novo mutation in the COL1A1 gene to underlie the severe osteogenesis imperfecta. Hum Genomics 9: 6, 2015.
14. Katoh M: Expression and regulation of Wnt1 in human cancer: Upregulation of Wnt1 by beta-estradiol in MCF-7 cells. Int J Oncol 22: 209-212, 2003.
15. Jia J, Jia S, Ji K and Jiing WG: Wnt1 inducible signalling pathway protein-2 (WISP-2/CCN5): Roles and regulation in human cancers (Review). Oncol Rep 31: 533-539, 2014.
16. Choi AR, Park JR, Kim RJ, Kim SR, Cho SD, Jung JY and Nam JS: Inhibition of Wnt1 expression reduces the enrichment of cancer stem cells in a mouse model of breast cancer. Biochem Biophys Res Commun 425: 436-442, 2012.
17. Keupp K, Beleggia F, Kayserili H, Barnes AM, Steiner M, Selmier O, Fischer B, Yigit G, Janda CY, Becker J, et al.: Mutations in WNT1 cause different forms of bone fragility. Am J Hum Genet 92: 565-574, 2013.
18. Joeng KS, Lee YC, Jiang MM, Bertin TK, Chen Y, Abraham AM, Ding H, Bi X, Ambrose CG and Lee BH: The swaying mouse as a model of osteogenesis imperfecta caused by WNT1 mutations. Hum Mol Genet 23: 4035-4042, 2014.
19. Kato M, Nakatani Y, Kanno H, Inayama Y, Jiri R, Nagahara N, Miyake T, Tanaka M, Ito Y, Aida N, et al.: Possible linkage between specific histological structures and aberrant reaction of Wnt pathway in adamantinomatous craniopharyngioma. J Pathol 203: 814-821, 2004.
20. Fuchs-Young R, Shirley SH, Lambertz I, Colby JK, Tian J, Johnston D, Gimenez-Conti IB, Donehower LA, Conti CJ and Hursting SD: P53 genotype as a determinant of ER expression and tamoxifen response in the MMTV-Wnt-1 model of mammary carcinogenesis. Breast Cancer Res Treat 130: 399-408, 2011.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.